Celanese (CE) EPS Estimated At $2.30; Bioscrip (BIOS) SI Decreased By 3.28%

June 19, 2018 - By Richard Conner

BioScrip, Inc. (NASDAQ:BIOS) Logo

Bioscrip Inc (NASDAQ:BIOS) had a decrease of 3.28% in short interest. BIOS’s SI was 11.27M shares in June as released by FINRA. Its down 3.28% from 11.65 million shares previously. With 905,000 avg volume, 13 days are for Bioscrip Inc (NASDAQ:BIOS)’s short sellers to cover BIOS’s short positions. The SI to Bioscrip Inc’s float is 9.93%. The stock increased 0.37% or $0.01 during the last trading session, reaching $2.7. About 427,550 shares traded. BioScrip, Inc. (NASDAQ:BIOS) has risen 39.44% since June 19, 2017 and is uptrending. It has outperformed by 26.87% the S&P500. Some Historical BIOS News: ; 08/03/2018 – BioScrip: Review Is Ongoing; 26/03/2018 – BIOSCRIP CONCLUDES ACCOUNTING REVIEW; 08/03/2018 – BioScrip May Report One or More Internal Control Material Weaknesses in Form 10-K; 15/05/2018 – WYNNEFIELD CAPITAL REDUCED DLHC, CLAR, BIOS, MVC, NEPT IN 1Q; 29/05/2018 – BioScrip Presenting at Conference Tomorrow; 08/03/2018 – BioScrip Accounting Review Identifies ‘internal Control Deficiencies’ And ‘material Weakness’ — MarketWatch; 26/03/2018 – BIOSCRIP- FY2017 RESULTS REFLECT ANTICIPATED IMMATERIAL CORRECTIONS TO PRELIM FINANCIAL RESULTS REPORTED IN CO’S PRESS RELEASE DATED MARCH 8; 16/05/2018 – BioScrip at Non-Deal Roadshow Hosted By SunTrust Today; 08/03/2018 – BIOSCRIP INC – QTRLY PRELIMINARY NET REVENUE OF $182.6 MLN, INCLUDING CORE PRODUCT MIX OF 75.7%, COMPARED TO 69.6% IN PRIOR YEAR QUARTER; 08/03/2018 – BioScrip Identified Internal Control Deficiencies

Analysts expect Celanese Corporation (NYSE:CE) to report $2.30 EPS on July, 23.They anticipate $0.51 EPS change or 28.49% from last quarter’s $1.79 EPS. CE’s profit would be $312.47 million giving it 12.45 P/E if the $2.30 EPS is correct. After having $2.79 EPS previously, Celanese Corporation’s analysts see -17.56% EPS growth. The stock decreased 2.04% or $2.39 during the last trading session, reaching $114.57. About 956,548 shares traded. Celanese Corporation (NYSE:CE) has risen 31.06% since June 19, 2017 and is uptrending. It has outperformed by 18.49% the S&P500. Some Historical CE News: ; 30/04/2018 – CELANESE EXTENDS EXCLUSIVE ACETYLS R&D TECHNOLOGY PACT WITH SWR; 19/03/2018 – CELANESE STATEMENT ON WITHDRAWAL OF EC NOTIFICATION; 20/04/2018 – Celanese Appoints Benita Casey as Chief Accounting Officer; 30/04/2018 – Celanese Announces GUR Capacity Expansion at Its Nanjing, China Engineered Materials Manufacturing Facility; 20/03/2018 – Celanese Closes Below 200-Day Moving Average: Technicals; 20/04/2018 – Celanese Forms Golden Cross: Technicals; 16/04/2018 – CELANESE CORP – “CAN GROW ADJUSTED EARNINGS PER SHARE BY 20-25 PERCENT IN 2018”; 19/03/2018 – Celanese and Blackstone Joint Venture Called Off Following European Opposition; 30/05/2018 – Celanese Announces Emulsions, VAM Product Price Increases; 16/04/2018 – Celanese 1Q Net $363M

Among 6 analysts covering BioScrip (NASDAQ:BIOS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioScrip had 15 analyst reports since August 11, 2015 according to SRatingsIntel. The company was maintained on Wednesday, August 9 by Jefferies. The company was downgraded on Tuesday, August 11 by SunTrust. Jefferies maintained BioScrip, Inc. (NASDAQ:BIOS) on Thursday, June 8 with “Buy” rating. The firm earned “Buy” rating on Wednesday, April 11 by Barrington. SunTrust maintained BioScrip, Inc. (NASDAQ:BIOS) rating on Thursday, March 8. SunTrust has “Buy” rating and $3.25 target. Dougherty & Company maintained the stock with “Buy” rating in Wednesday, August 12 report. The firm has “Buy” rating by Jefferies given on Thursday, November 2. As per Tuesday, January 3, the company rating was initiated by Lake Street. SunTrust upgraded the stock to “Buy” rating in Thursday, August 10 report. As per Tuesday, July 25, the company rating was maintained by Jefferies.

BioScrip, Inc. provides home infusion services in the United States. The company has market cap of $345.47 million. The firm engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. It currently has negative earnings. It is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Investors sentiment increased to 1.39 in 2018 Q1. Its up 0.21, from 1.18 in 2017Q4. It increased, as 10 investors sold BioScrip, Inc. shares while 26 reduced holdings. 16 funds opened positions while 34 raised stakes. 106.54 million shares or 2.37% more from 104.07 million shares in 2017Q4 were reported. Archer Capital Mgmt Ltd Partnership holds 2.19% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS) for 1.57M shares. Geode Ltd Liability Company reported 1.13M shares. Citigroup reported 600 shares or 0% of all its holdings. Raymond James & reported 144,800 shares. Salzhauer Michael holds 34,075 shares. Sg Americas Securities holds 17,931 shares or 0% of its portfolio. Ares Mngmt Lc invested 0.56% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS). Ameritas Partners Inc holds 0% in BioScrip, Inc. (NASDAQ:BIOS) or 9,711 shares. Manufacturers Life The has 90,436 shares. San Francisco Sentry Invest Gp (Ca) owns 200 shares. Goldman Sachs Group holds 0% or 73,163 shares. Parametric Assocs Llc reported 0% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS). New York-based Jpmorgan Chase & Communication has invested 0% in BioScrip, Inc. (NASDAQ:BIOS). Tudor Investment Corporation Et Al reported 117,305 shares. M&T Bank & Trust Corp owns 0% invested in BioScrip, Inc. (NASDAQ:BIOS) for 80,000 shares.

Among 19 analysts covering Celanese (NYSE:CE), 14 have Buy rating, 1 Sell and 4 Hold. Therefore 74% are positive. Celanese had 80 analyst reports since September 1, 2015 according to SRatingsIntel. Citigroup downgraded Celanese Corporation (NYSE:CE) rating on Wednesday, September 7. Citigroup has “Neutral” rating and $71 target. Cowen & Co maintained the stock with “Outperform” rating in Wednesday, February 15 report. The company was maintained on Wednesday, July 27 by Barclays Capital. Citigroup maintained Celanese Corporation (NYSE:CE) on Friday, July 15 with “Buy” rating. The firm has “Neutral” rating by UBS given on Tuesday, October 17. RBC Capital Markets maintained the stock with “Sector Perform” rating in Wednesday, October 21 report. Susquehanna initiated the shares of CE in report on Friday, July 1 with “Positive” rating. The firm earned “Outperform” rating on Friday, February 17 by Robert W. Baird. The stock has “Buy” rating by RBC Capital Markets on Monday, June 5. RBC Capital Markets maintained the stock with “Buy” rating in Monday, June 19 report.

Celanese Corporation, a technology and specialty materials company, makes and sells value-added chemicals, thermoplastic polymers, and other chemical products worldwide. The company has market cap of $15.57 billion. The company??s Advanced Engineered Materials segment develops, produces, and supplies specialty polymers for automotive and medical applications, as well as for use in industrial products and consumer electronics. It has a 15.36 P/E ratio. The Company’s Consumer Specialties segment provides cellulose acetate flakes, films, and tows for use in filter products applications; food protection ingredients, such as potassium sorbate and sorbic acid for food and beverage industry; Sunett, a sweetener for use in various beverages, confections, and dairy products; and Qorus, a sweetener system designed for low-to no-calorie carbonated and non-carbonated beverages, flavored waters, energy drinks, and milk and dairy products.

More news for Celanese Corporation (NYSE:CE) were recently published by: Globenewswire.com, which released: “New Research: Key Drivers of Growth for Global Payments, Patterson-UTI Energy, Celanese, Westlake Chemical, Las …” on June 12, 2018. Benzinga.com‘s article titled: “10 Biggest Price Target Changes For Friday” and published on June 15, 2018 is yet another important article.

Investors sentiment decreased to 0.85 in Q1 2018. Its down 0.20, from 1.05 in 2017Q4. It is negative, as 38 investors sold Celanese Corporation shares while 158 reduced holdings. 53 funds opened positions while 114 raised stakes. 122.66 million shares or 1.97% less from 125.13 million shares in 2017Q4 were reported. Moreover, First Tru Advsr L P has 0.04% invested in Celanese Corporation (NYSE:CE) for 171,089 shares. 71,029 were accumulated by Axa. Alyeska Gru Lp stated it has 0.04% of its portfolio in Celanese Corporation (NYSE:CE). Envestnet Asset Mgmt Inc owns 1,698 shares for 0% of their portfolio. Alps accumulated 0% or 4,458 shares. Wagner Bowman Management Corporation invested in 0.28% or 10,128 shares. Washington-based Parametric Portfolio Associates has invested 0.03% in Celanese Corporation (NYSE:CE). Fulton Bancorporation Na has 0.03% invested in Celanese Corporation (NYSE:CE). Wedge Capital Mngmt L Lp Nc holds 0.08% or 79,797 shares. Deutsche Bancorporation Ag, a Germany-based fund reported 395,159 shares. Los Angeles Capital Mngmt Equity Research Incorporated owns 26,300 shares for 0.01% of their portfolio. Schroder Inv Management Gru has 0% invested in Celanese Corporation (NYSE:CE) for 4,600 shares. Pggm invested in 0.12% or 204,400 shares. 7,943 were accumulated by Livforsakringsbolaget Skandia Omsesidigt. Atria Ltd Limited Liability Company has invested 0.01% in Celanese Corporation (NYSE:CE).

Celanese Corporation (NYSE:CE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: